[go: up one dir, main page]

WO1996007415B1 - Myocardial protection using benzothiazepinones - Google Patents

Myocardial protection using benzothiazepinones

Info

Publication number
WO1996007415B1
WO1996007415B1 PCT/CA1995/000514 CA9500514W WO9607415B1 WO 1996007415 B1 WO1996007415 B1 WO 1996007415B1 CA 9500514 W CA9500514 W CA 9500514W WO 9607415 B1 WO9607415 B1 WO 9607415B1
Authority
WO
WIPO (PCT)
Prior art keywords
represents hydrogen
methyl
compound
reperfusion
myocardial protection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1995/000514
Other languages
French (fr)
Other versions
WO1996007415A1 (en
Filing date
Publication date
Priority claimed from US08/303,826 external-priority patent/US5580867A/en
Application filed filed Critical
Priority to AU33781/95A priority Critical patent/AU3378195A/en
Priority to EP95930352A priority patent/EP0779811A1/en
Priority to KR1019970701573A priority patent/KR970705396A/en
Priority to BR9508907A priority patent/BR9508907A/en
Priority to JP8509064A priority patent/JPH10505350A/en
Publication of WO1996007415A1 publication Critical patent/WO1996007415A1/en
Publication of WO1996007415B1 publication Critical patent/WO1996007415B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

Myocardial protection is achieved by administering to a patient an effective amount of a benzothiazepin derivative. The benzothiazepin derivatives have general chemical formula (I), wherein R1 represents hydrogen or methyl, R2 represents hydrogen or acetyl, R3 represents hydrogen or methyl, and R4 represents hydrogen or a halogen, with the proviso that R1 cannot be methyl when R2 = acetyl, R3 = methyl and R4 = hydrogen. The above compounds may also be used in other clinical conditions such as treatment of stable and unstable angina, non-Q-wave myocardial infarction, cerebral trauma ischemia and reperfusion, organ graft preservation, etc.

Claims

AMENDED CLAIMS[received by the International Bureau on 4 March 1996 (04.03.96); original claims 1, 3 and 4 amended; original claims 5-7 cancelled; remaining claim unchanged (2 pages)]
1. Method of providing myocardial protection in a patient during ischemia and reperfusion which comprises administering to said patient an effective amount of a compound of formula:
Figure imgf000003_0001
(2R,3R)
wherein
Rj represents methyl, R2 represents hydrogen,
R3 represents hydrogen, and
RA represents hydrogen or a halogen, or a pharmaceutically acceptable salt thereof.
2. Method according to claim 1, wherein said compound is administered before or after coronary occlusion up to a few minutes before and during coronary reperfusion.
3. Method according to claim 2, wherein said compound is administered intravenously at doses of about 20 to about 200 mg.
4. Method according to claim 1, wherein said compound has the formula:
-20-
Figure imgf000004_0001
(2R,3R)
or a salt thereof.
PCT/CA1995/000514 1994-09-09 1995-09-11 Myocardial protection using benzothiazepinones Ceased WO1996007415A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU33781/95A AU3378195A (en) 1994-09-09 1995-09-11 Myocardial protection using benzothiazepinones
EP95930352A EP0779811A1 (en) 1994-09-09 1995-09-11 Myocardial protection using benzothiazepinones
KR1019970701573A KR970705396A (en) 1994-09-09 1995-09-11 Myocardial protection using benzothiazepine
BR9508907A BR9508907A (en) 1994-09-09 1995-09-11 Myocardial protection using benzothiazepinones
JP8509064A JPH10505350A (en) 1994-09-09 1995-09-11 Myocardial protection with benzothiazepinone

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/303,826 1994-09-09
US08/303,826 US5580867A (en) 1994-09-09 1994-09-09 Myocardial protection during ischemia and reperfusion

Publications (2)

Publication Number Publication Date
WO1996007415A1 WO1996007415A1 (en) 1996-03-14
WO1996007415B1 true WO1996007415B1 (en) 1996-04-11

Family

ID=23173874

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1995/000514 Ceased WO1996007415A1 (en) 1994-09-09 1995-09-11 Myocardial protection using benzothiazepinones

Country Status (8)

Country Link
US (1) US5580867A (en)
EP (1) EP0779811A1 (en)
JP (1) JPH10505350A (en)
KR (1) KR970705396A (en)
AU (1) AU3378195A (en)
BR (1) BR9508907A (en)
CA (1) CA2198862A1 (en)
WO (1) WO1996007415A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157437A0 (en) * 2003-07-14 2004-03-28 Superseal Ltd Superseal Ltd Hydrophobic aggregate and applications thereof
EP2131657A1 (en) * 2007-02-28 2009-12-16 Merck & Co., Inc. Substituted benzodiazepinones, benzoxazepinones and benzothiazepinones as sodium channel blockers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58113185A (en) * 1981-12-28 1983-07-05 Hamari Yakuhin Kogyo Kk Novel benzothiazepin derivative and its preparation
US4520112A (en) * 1983-03-09 1985-05-28 The Johns Hopkins University Assay method for organic calcium antagonist drugs and a kit for such an assay
US4585768A (en) * 1984-04-10 1986-04-29 Tanabe Seiyaku Co., Ltd. 1,5-benzothiazepine derivatives and processes for preparing the same
JPS62161776A (en) * 1986-01-07 1987-07-17 Tanabe Seiyaku Co Ltd Production of 1,5-benzothiazepine derivative
FR2597097B1 (en) * 1986-04-15 1988-12-02 Synthelabo BENZOTHIAZEPINE-1, 5 DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
US4950663A (en) * 1989-02-15 1990-08-21 Louis Dumont Antihypertensive composition

Similar Documents

Publication Publication Date Title
CA2212856A1 (en) Benzopyran-containing compounds and method for their use
CA2261799A1 (en) Composition comprising insulin and insulin-like growth factor-i (igf-i)
KR950017957A (en) Preparation and intermediates of 3, 4, 4-trisubstituted-piperidinyl-N-alkylcarboxylates
KR930003912A (en) Congestive Heart Failure Treatment Cure
CA2098076A1 (en) Imidate prodrugs of pharmaceutically useful anticonvulsant sulfamates
KR890011592A (en) Composition for the treatment of endotracheal ischemia
JP2002519425A5 (en)
JP2001503780A5 (en)
JP2002537258A5 (en)
KR910016931A (en) Hypercholesterolemia Drugs
AU669122B2 (en) New pyrazine derivatives, their preparation and their use
CA1078736A (en) Therapeutic application of 4-carbamoyl-5-hydroxyimidazole
KR970707108A (en) (DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS)
CA2135614A1 (en) Use of urodilatin in pulmonary and bronchial diseases
US4181731A (en) Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
KR910004191A (en) Renal disease treatment
US4389415A (en) Method of treating hypertension
WO1996007415B1 (en) Myocardial protection using benzothiazepinones
KR900009647A (en) Adenosine derivatives, their preparation and method of use
KR970701545A (en) NEW USE OF QUINOLINE-3-CARBOXAMIDE COMPOUNDS
KR890012942A (en) 5-substituted ornithine derivatives
KR920021553A (en) Reduction product of rapamycin as an immunosuppressant, anti-inflammatory or antifungal agent
KR880009943A (en) Pyridazinone derivatives
CA2048235C (en) Lowering of blood uric acid levels
KR950016720A (en) How to inhibit the effects of amyloid protein